United States: FDA Holds Public Hearing On Manufacturer Communication Of Scientific And Medical Information

On November 9 and 10, 2016, FDA held a public hearing to obtain input on manufacturer communications involving unapproved uses of approved or cleared medical products (i.e., "off-label" uses). The hearing was moderated by Leslie Kux (Associate Commissioner for Policy, Office of the Commissioner) and included numerous high-ranking FDA officials as panelists, including Commissioner Robert Califf.1 Nearly sixty speakers, including members of the biopharmaceutical and medical device industries, health care professionals, patient and public health advocates, payers, and academics, testified at the hearing.

Ropes & Gray partner Kellie Combs (Washington, D.C.) spoke on behalf of the Medical Information Working Group ("MIWG"), urging the FDA to establish clear, constitutionally appropriate policies that permit biopharmaceutical and medical device manufacturers to share truthful and non-misleading scientific and medical information about their products with health care professionals and payers.

This Alert summarizes several key aspects of the hearing and describes its potential significance for regulated industry.

Overview of the Public Hearing

As discussed in a previous Ropes & Gray alert, FDA's Federal Register notice requested stakeholder comments about off-label communications and asked more than two dozen questions about whether and in what way FDA should change its regulations. Notably, while courts have held that truthful, non-misleading off-label speech is protected by the First Amendment, and that the Fifth Amendment requires government agencies such as FDA to issue clear and narrowly tailored rules when regulating speech, the Federal Register notice made only a single, passing reference to constitutional developments.

In his opening remarks, Dr. Califf spoke about the rationale for the agency's speech restrictions, emphasizing the importance of premarket review of new uses of approved products and describing several commonly cited examples of the potential harms that may result from off-label communications (e.g., the thalidomide case). He also acknowledged that FDA-approved or-cleared labeling does not contain all clinically relevant information, and he asked whether health care professionals currently faced challenges in accessing off-label information.

More than half of the speakers advocated for broader allowances for manufacturer communications, arguing that the provision of clear pathways for manufacturers to communicate truthful, non-misleading, clinically relevant off-label information is critical to the public health and consistent with constitutional requirements. Many of the speakers, however, favored tighter FDA restrictions on manufacturer speech, though they generally grounded their arguments in the potential dangers associated with lawful off-label use rather than off-label communications by manufacturers.

Presentations in Favor of Greater Flexibility and Clarity in FDA's Regulatory Scheme

Speakers in favor of broader dissemination of truthful and non-misleading scientific and medical information asserted that manufacturers are often able to provide valuable and unique insights to both payers and healthcare professionals, and that FDA's current framework sharply limits manufacturers from sharing information even when consistent with the approved or cleared indication. Speakers also explained that, in addition to the public health benefits associated with greater flexibility to engage in off-label communications, the First and Fifth Amendments prohibit the government from restricting truthful and non-misleading speech unless the rules are clear and are narrowly drawn to advance a compelling government interest. Health care professionals argued that they benefit from receiving up-to-date information that, in many cases, only manufacturers are able to provide, and payers explained the significant advantages early pipeline communications with manufacturers would have on formulary planning and insurance rates. Numerous patient groups contended that off-label communications are necessary in the context of rare diseases such as lupus and pediatric cancer, where on-label treatments are either ineffective or unavailable.

Presentations in Favor of the Status Quo or Enhanced FDA Regulation

Several speakers, including academics and physicians, also advocated on behalf of FDA's current regulatory regime, and some argued that FDA should impose broader restrictions, limiting all forms of manufacturer communication about unapproved uses. These speakers asserted that off-label communications are invariably detrimental to the public health, expressing concerns that modifications to FDA's regulatory framework would increase off-label prescribing and that manufacturers would share low-quality data or misleading information. Speakers also contested the impact of the recent constitutional case law, arguing that FDA's public health mission should take precedence over speech arguments raised by industry or other advocates for greater flexibility in the agency's regulatory regime.

FDA will accept written comments from interested stakeholders until January 9, 2017.

Implications of the Public Hearing

The FDA panelists were noticeably engaged during the public hearing, and most speakers received multiple questions. It was evident from the questions that the agency is cognizant of the public health value of off-label information, particularly with respect to serious or life-threatening conditions and in therapeutic areas where on-label treatments are limited. However, it was also clear that FDA remains uncomfortable with significantly relaxing long-standing agency rules and is grappling with the potential impact that constitutional case law has on its highly restrictive regulatory framework.

The ultimate impact of the public hearing is difficult to predict. When FDA granted two citizen petitions submitted by the members of the MIWG in 2014, it stated that it was engaged in a comprehensive review of its regulations and policies governing manufacturer speech and promised to issue four relevant guidance documents by the end of that year. FDA has still not issued those guidance documents or otherwise taken any meaningful action to clarify or modify its regulatory scheme.


1 The full panel included Rachel E. Sherman (Deputy Commissioner for Medical Products and Tobacco), Kristin Davis (Senior Policy Advisor, Office of Policy, Office of the Commissioner), Karen E. Schifter (Senior Counsel, Office of the Chief Counsel, Office of the Commissioner), Diane Maloney (Associate Director for Policy, Center for Biologics Evaluation Research), Thomas Abrams (Director, Office of Prescription Drug Promotion, Center for Drug Evaluation and Research), Lauren Silvis (Deputy Director for Policy, Center for Devices and Radiological Health), and Dorothy McAdams (Supervisory Veterinary Medical Officer, Office of Surveillance and Compliance, Center for Veterinary Medicine).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions